Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Liver Transplantation and Metastatic Colo-rectal Cancer.

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Svein Dueland, Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT00294827
First received: February 21, 2006
Last updated: March 30, 2016
Last verified: March 2016
  Purpose
Survival of colo-rectal cancer patients after liver transplantation.

Condition Intervention Phase
Colo-rectal Cancer
Procedure: Liver transplantation and colo-rectal cancer
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Liver Transplantation and Metastatic Colo-rectal Cancer.

Resource links provided by NLM:


Further study details as provided by Oslo University Hospital:

Primary Outcome Measures:
  • Survival [ Time Frame: 6 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time to progression side-effects [ Time Frame: 6 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 25
Study Start Date: February 2006
Estimated Study Completion Date: May 2023
Estimated Primary Completion Date: May 2022 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Liver transplantation Procedure: Liver transplantation and colo-rectal cancer
Liver transplantation

Detailed Description:
Survival, time to progression, other malignancy, side-effects, quality of life.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:Colo-rectal cancer -

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00294827

Locations
Norway
Rikshospitalet-Radiumhospitalet HF
Oslo, Norway, 0020
Sponsors and Collaborators
Oslo University Hospital
Investigators
Principal Investigator: Svein Dueland, MD, PhD Rikshospitalet-Radiumhospitalet RRHF
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Svein Dueland, MD PhD, Oslo University Hospital
ClinicalTrials.gov Identifier: NCT00294827     History of Changes
Other Study ID Numbers: S-05409 (SECA I) 
Study First Received: February 21, 2006
Last Updated: March 30, 2016
Health Authority: Norway: South region committee for research ethics in Norway

Keywords provided by Oslo University Hospital:
Liver transplantation

Additional relevant MeSH terms:
Rectal Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Colonic Diseases
Liver Extracts
Hematinics

ClinicalTrials.gov processed this record on September 28, 2016